摘要
目的：探讨乳腺癌患者的ｐ糖蛋白表达与生存率、ｎｍ２３抑制癌转移基因与淋巴结转移之间的关系。方法：应用免疫组化Ｓ－Ｐ法，观察随访１０年以上的乳腺癌组织中ｐ糖蛋白和ｎｍ２３蛋白的表达。结果：ｐ糖蛋白和ｎｍ２３的阳性表达率分别为３６．５０％和９５．１２％。ｐ糖蛋白的阳性表达率仅与乳腺癌患者生存率有关（Ｐ＜０．０１），１０年以上较低，而与乳腺癌组织学分型，组织学分级，临床分期、淋巴结转移等无明显相关（Ｐ＞０．０５）。ｎｍ２３蛋白的阳性表达强度与乳腺癌腋窝淋巴结转移之间呈非常显著性负相关（Ｐ＜０．０１）。结论：乳腺癌组织ｐ糖蛋白和ｎｍ２３蛋白的检测对乳腺癌患者的预后判断及治疗方案的选择、淋巴结转移的预测均有积极的临床意义。
Purpose To investigate whether or not an interrelationship exists between the expression of pglycoprotein and surviral, nm23 oncogene and lymph node metastasis in breast cancer. Methods The expressions of pglycoprotein (pgp) and nm23 oncogene products were studied by using immunohistochemistry on 82 patients with breast carcinoma and all patients were followed up 10 years. Results The expressions of pgp and nm23 were 365% and 951%, respectively. There were statistically significance between 5 years and 10 years surviral (P<001) for two oncogene markers. No relationship was found between these markers expression and other prognostic factors including tumor grade, histologic types, lymph node metastasis and clinic grade (P>005). There was a significant inverse relationship between nm23 expression and nodal states (P<001). Conclusions There is a significant clinic value to detect pgp and nm23 for prognosis, lymph node metastasis and therapy design in patients with breast carcinomas.
出处
《临床与实验病理学杂志》
CAS
CSCD
1997年第4期305-307,I030,共4页
Chinese Journal of Clinical and Experimental Pathology
